These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 37738842)

  • 1. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma.
    Zhang Q; Zhang J; Tian Y; Wang J; Jin G; Liu F
    Virology; 2023 Oct; 587():109885. PubMed ID: 37738842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
    Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
    Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells loaded with Ad5-Ki67/IL-15 enhance oncolytic adenovirotherapy in experimental glioblastoma.
    Wang P; Zhang J; Zhang Q; Liu F
    Biomed Pharmacother; 2023 Jan; 157():114035. PubMed ID: 36434955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.
    Zhang Q; Zhang J; Tian Y; Zhu G; Liu S; Liu F
    Cell Biosci; 2020; 10():124. PubMed ID: 33133514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TS-2021, a third-generation oncolytic adenovirus that carried Ki67 promoter, TGF-β2 5'UTR, and IL-15 against experimental glioblastoma.
    Wang J; Zhang J; Zhang Q; Zhang W; Zhang Q; Jin G; Liu F
    J Med Virol; 2024 Jan; 96(1):e29335. PubMed ID: 38149454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.
    Klawitter M; El-Ayoubi A; Buch J; Rüttinger J; Ehrenfeld M; Lichtenegger E; Krüger MA; Mantwill K; Koll FJ; Kowarik MC; Holm PS; Naumann U
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma.
    Chen L; Zhou C; Chen Q; Shang J; Liu Z; Guo Y; Li C; Wang H; Ye Q; Li X; Zu S; Li F; Xia Q; Zhou T; Li A; Wang C; Chen Y; Wu A; Qin C; Man J
    Mol Ther Oncolytics; 2022 Mar; 24():522-534. PubMed ID: 35229030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
    Zhang J; Guo Y; Fang H; Guo X; Zhao L
    Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition.
    Sun Y; Zhang Z; Zhang C; Zhang N; Wang P; Chu Y; Chard Dunmall LS; Lemoine NR; Wang Y
    Mol Ther Oncolytics; 2022 Sep; 26():105-119. PubMed ID: 35795092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity.
    Qi Z; Zhao J; Li Y; Zhang B; Hu S; Chen Y; Ma J; Shu Y; Wang Y; Cheng P
    Front Immunol; 2023; 14():982180. PubMed ID: 37114043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
    Qiao J; Dey M; Chang AL; Kim JW; Miska J; Ling A; M Nettlebeck D; Han Y; Zhang L; Lesniak MS
    Oncoimmunology; 2015 Aug; 4(8):e1022302. PubMed ID: 26405578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
    Li M; Li G; Kiyokawa J; Tirmizi Z; Richardson LG; Ning J; Das S; Martuza RL; Stemmer-Rachamimov A; Rabkin SD; Wakimoto H
    Acta Neuropathol Commun; 2020 Dec; 8(1):221. PubMed ID: 33308315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
    Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
    Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
    Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
    Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
    Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.